NCT03396822View on ClinicalTrials.gov

Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

CompletedOBSERVATIONAL

Enrollment

24

Participants

Timeline

Start Date

September 24, 2018

Primary Completion Date

May 25, 2023

Study Completion Date

May 25, 2023

Conditions

Multiple Sclerosis

Interventions

DRUG

Gadoteridol

gadolinium MRI contrast

Trial Locations (1)

21201

University of Maryland School of Medicine, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT03396822 - Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis | Biotech Hunter | Biotech Hunter